News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Liang Cheng: Current androgen receptor antagonists under investigation for resistant prostate cancer
Liang Cheng/X
Mar 20, 2025, 15:51

Liang Cheng: Current androgen receptor antagonists under investigation for resistant prostate cancer

Liang Cheng, Vice Chair for Translational Research at Warren Alpert Medical School of Brown University, shared his recent article on X:

“I am delighted to share this NEWEST article from Expert Review of Anticancer Therapy!

Congratulations to Professor Francesco Massari, Linda Danielli, and the Team.”

Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges

Authors: Linda Danielli, et al.

Liang Cheng: Current androgen receptor antagonists under investigation for resistant prostate cancer

Summary of the article:

  • Prostate cancer progression is largely driven by androgen receptor (AR) signaling, making androgen receptor signaling inhibitors (ARSIs) a cornerstone of treatment for castration-resistant prostate cancer (CRPC). However, resistance mechanisms necessitate novel therapeutic approaches.
  • Recent advancements focus on combination therapies, including ARSIs with PARP inhibitors (PROpel, MAGNITUDE, TALAPRO-2 trials), radioligand therapies (radium-223, lutetium-177), and novel agents targeting DNA repair and alternative signaling pathways.
  • Future directions emphasize biomarker-driven treatment selection, optimized therapy sequencing, and innovative strategies to overcome resistance, aiming to enhance clinical outcomes and personalize care in CRPC management.

More posts featuring Liang Cheng.

androgen receptor antagonists anticancer therapy cancer fight against cancer Francesco Massari Global awareness Global fight against cancer Liang Cheng Linda Danielli OncoDaily Oncology prostate cancer resistant prostate cancer
Special Coverage
Science
Mar 20, 2025, 15:51
Liang Cheng: Current androgen receptor antagonists under investigation for resistant prostate cancer
Blog
Mar 20, 2025, 15:25
Norman Ng: China’s R and D of PD-1 Immunotherapy Drugs - A Future Hope for Hong Kong?
Blog
Mar 20, 2025, 15:17
Dean Crowe: $75 MILLION for kids, teens, and young adults fighting cancer
Blog
Mar 20, 2025, 14:47
Eric Zwanenburg: The Princess Máxima Center and Google Cloud are developing an AI tool called Capricorn
Blog
Mar 20, 2025, 11:46
What happens when women not only have a seat at the table but also shape the agenda? - Kearney
Blog
Mar 20, 2025, 11:39
Susanna Fletcher Greer: Understanding cellular communication in colorectal adenocarcinoma
Blog
Mar 20, 2025, 11:30
Abstract Submission open for MAP 2025 - ESMO
Science
Mar 20, 2025, 11:22
Ashish M. Kamat: Impact of fellowship training on outcomes and complication rates of radical prostatectomy
Radiotherapy
Mar 20, 2025, 11:18
What Is Superficial Radiotherapy and How It Works? Pros and Cons
Blog
Mar 20, 2025, 11:13
Francisco Conesa Buendía: AstraZeneca’s $1B Bet on In Vivo CAR-T - A Potential Game-Changer for Cancer Therapy
Blog
Mar 20, 2025, 11:01
Polikalipo Kagina: World Radiotherapy Day 2025 Officially Set for September 7
Science
Mar 20, 2025, 10:52
Nihar Desai: Central Nervous System Manifestations of Graft-Versus-Host Disease